<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03146988</url>
  </required_header>
  <id_info>
    <org_study_id>RGB-02-001</org_study_id>
    <nct_id>NCT03146988</nct_id>
  </id_info>
  <brief_title>Study to Compare the Pharmacokinetics and Pharmacodynamics of 6 mg RGB-02 to 6 mg Neulasta</brief_title>
  <official_title>Randomised, Double-Blind, Single, 6 mg Fixed Dose, Two Treatment, Two-Period, Two-Sequence, Two-Way Crossover Comparative Pharmacokinetic and Pharmacodynamic (Phase I) Study of RGB-02 Compared to Neulasta® in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gedeon Richter Plc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gedeon Richter Plc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single-centre, double-blind, randomised, two-period, two-way crossover study to investigate
      the pharmacokinetics and pharmacodynamics of RGB-02 as compared to Neulasta® administered as
      a single subcutaneous injection in healthy adult subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 10, 2017</start_date>
  <completion_date type="Actual">October 4, 2017</completion_date>
  <primary_completion_date type="Actual">September 14, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic parameter: AUC0-inf</measure>
    <time_frame>67 days</time_frame>
    <description>Area under the serum concentration vs time curve from dosing to the last measured time point</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameter: Cmax</measure>
    <time_frame>67 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamic parameter: ANCmax</measure>
    <time_frame>67 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamic parameter: ANC AOBEC0-tlast</measure>
    <time_frame>67 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Bioequivalence</condition>
  <arm_group>
    <arm_group_label>RGB-02 6 mg SC (test product)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Neulasta®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RGB-02 or Neulasta® (pegfilgrastim)</intervention_name>
    <description>Pre-filled syringe containing 6 mg RGB-02 or Neulasta® in 0.6 mL, administered as subcutaneous injection into the abdominal area</description>
    <arm_group_label>RGB-02 6 mg SC (test product)</arm_group_label>
    <arm_group_label>Neulasta®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males or non-pregnant, non-lactating healthy females aged 18 to 55 years

          -  Body mass index ≥19.0 to ≤30.0 kg/m2

          -  Body weight &gt;55 kg&quot;

        Exclusion Criteria:

          -  Prior exposure to filgrastim, pegfilgrastim or lenograstim (Period 1 only)

          -  Subjects who have received any IMP in a clinical research study within the previous 3
             months

          -  History of any drug or alcohol abuse in the past 2 years

          -  Regular alcohol consumption in males &gt;21 units per week and females &gt;14 units per week
             (1 unit = ½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine)

          -  Current smokers who smoke more than 10 cigarettes per day

          -  Positive drugs of abuse test result

          -  Serious adverse reaction or serious hypersensitivity to any drug or the formulation
             excipients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Quotient Clinical</name>
      <address>
        <city>Ruddington</city>
        <state>Nottingham</state>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2017</study_first_submitted>
  <study_first_submitted_qc>May 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2017</study_first_posted>
  <last_update_submitted>November 21, 2017</last_update_submitted>
  <last_update_submitted_qc>November 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

